Here the authors report a phase 3 clinical trial showing that Ecnoglutide, designed as a cAMP-biased GLP-1R agonist, improved glycaemic control versus placebo in adults with type 2 diabetes inadequately controlled with diet and exercise alone or with a single oral hypoglycaemic agent.
- Dalong Zhu
- Weimin Wang
- Hai Pan
